Novo Nordisk upgrades guidance

The Danish pharmaceutical giant has upgraded its full-year financial guidance due to the growth in market shares for diabetes drug Ozempic being higher than expected and market growth for the other GLP analogs. Obesity drug sales, mostly in the US, are also highlighted as significant.

Photo: Novo Nordisk / PR

Novo Nordisk has raised its sales and operating outlook for 2021.

This comes after the firm ended Q3 with a 15 percent increase in net sales and a 19 percent increase in operating profits, measured in constant exchange rates (CER). For the first nine months of the year, Novo reports net revenue growth of 13 percent and an operating result growth of 12 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs